{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:57:09Z","timestamp":1789207029116,"version":"build-2803163510"},"reference-count":34,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on the differentiation arrest phenotype observed during progression of CML and in BCR-ABL+ ALL.<\/jats:p>","DOI":"10.1182\/blood-2007-07-102533","type":"journal-article","created":{"date-parts":[[2008,1,18]],"date-time":"2008-01-18T01:54:01Z","timestamp":1200621241000},"page":"3735-3741","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":60,"title":["RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance"],"prefix":"10.1182","volume":"111","author":[{"given":"Catherine","family":"Roche-Lestienne","sequence":"first","affiliation":[{"name":"Cancer Research Institute of Lille, JP Aubert Center, Inserm Unit 837, Lille, and North-West Canc\u00e9rop\u00f4le;"},{"name":"Laboratory for Medical Genetics Centre Hospitalier R\u00e9gional Universitaire (CHRU), Lille;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laur\u00e9line","family":"Deluche","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of Lille, JP Aubert Center, Inserm Unit 837, Lille, and North-West Canc\u00e9rop\u00f4le;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9lim","family":"Corm","sequence":"additional","affiliation":[{"name":"Hematology Department, CHRU, Lille;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Tigaud","sequence":"additional","affiliation":[{"name":"Laboratory for Hematology and Cytogenetics, Centre Hospitalier Lyon Sud (CHLS), Pierre-B\u00e9nite;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Joha","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of Lille, JP Aubert Center, Inserm Unit 837, Lille, and North-West Canc\u00e9rop\u00f4le;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Philippe","sequence":"additional","affiliation":[{"name":"Laboratory for Hematology, Biology and Pathology Center, CHRU, Lille; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Geffroy","sequence":"additional","affiliation":[{"name":"Laboratory for Hematology, Biology and Pathology Center, CHRU, Lille; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"La\u00ef","sequence":"additional","affiliation":[{"name":"Laboratory for Medical Genetics Centre Hospitalier R\u00e9gional Universitaire (CHRU), Lille;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck-Emmanuel","family":"Nicolini","sequence":"additional","affiliation":[{"name":"Hematology Department, E. Herriot Hospital, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[{"name":"Cancer Research Institute of Lille, JP Aubert Center, Inserm Unit 837, Lille, and North-West Canc\u00e9rop\u00f4le;"},{"name":"Laboratory for Hematology, Biology and Pathology Center, CHRU, Lille; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111801082045200_B1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia: advances in biology and new approaches to treatment.","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"2019111801082045200_B2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/asheducation-2005.1.118","article-title":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.","author":"Ottmann","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111801082045200_B3","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukemia.","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"2019111801082045200_B4","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial.","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"key":"2019111801082045200_B5","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis.","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"2019111801082045200_B6","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1073\/pnas.0604716104","article-title":"Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.","volume":"104","author":"Miething","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111801082045200_B7","first-page":"1789","article-title":"Core-binding factor: a central player in hematopoiesis and leukemia.","volume":"59","author":"Speck","year":"1999","journal-title":"Cancer Res"},{"key":"2019111801082045200_B8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/geno.1994.1519","article-title":"AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization.","volume":"23","author":"Levanon","year":"1994","journal-title":"Genomics"},{"key":"2019111801082045200_B9","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood.V96.8.2862","article-title":"High incidence of biallelic point mutations in the Runt domain of the AML1\/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.","volume":"96","author":"Preudhomme","year":"2000","journal-title":"Blood"},{"key":"2019111801082045200_B10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/sj.leu.2402766","article-title":"New mechanisms of AML1 gene alteration in hematological malignancies.","volume":"17","author":"Roumier","year":"2003","journal-title":"Leukemia"},{"key":"2019111801082045200_B11","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1038\/sj.leu.2403931","article-title":"Coexistence of AML1\/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.","volume":"19","author":"Corm","year":"2005","journal-title":"Leukemia"},{"key":"2019111801082045200_B12","doi-asserted-by":"crossref","first-page":"8236","DOI":"10.1038\/sj.onc.1205095","article-title":"Cooperation of BCR-ABL and AML1\/MDS1\/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.","volume":"20","author":"Cuenco","year":"2001","journal-title":"Oncogene"},{"key":"2019111801082045200_B13","first-page":"751","article-title":"The molecular biology of chronic myeloid leukemia.","volume":"10","author":"Melo","year":"1996","journal-title":"Leukemia"},{"key":"2019111801082045200_B14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1128\/MCB.20.1.319-328.2000","article-title":"Biological characteristics of the leukemia-associated transcriptional factor AML1 disclosed by hematopoietic rescue of AML1-deficient embryonic stem cells by using a knock-in strategy.","volume":"20","author":"Okuda","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2019111801082045200_B15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1128\/MCB.18.1.322","article-title":"The t(8;21) fusion product, AML-1-ETO, associates with C\/EBP-alpha, inhibits C\/EBP-alpha-dependent transcription, and blocks granulocytic differentiation.","volume":"18","author":"Westendorf","year":"1998","journal-title":"Mol Cell Biol"},{"key":"2019111801082045200_B16","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood.V91.5.1688","article-title":"The AML1\/ETO(MTG8) and AML1\/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.","volume":"91","author":"Tanaka","year":"1998","journal-title":"Blood"},{"key":"2019111801082045200_B17","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/sj.leu.2404210","article-title":"Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML.","volume":"20","author":"Stevens-Kroef","year":"2006","journal-title":"Leukemia"},{"key":"2019111801082045200_B18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/gcc.20241","article-title":"Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22).","volume":"44","author":"Sakai","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111801082045200_B19","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/gcc.20370","article-title":"Overexpression of PRDM16 in the presence and absence of the RUNX1\/PRDM16 fusion gene in myeloid leukemias.","volume":"45","author":"Hazourli","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"2019111801082045200_B20","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"2019111801082045200_B21","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"2019111801082045200_B22","article-title":"International System for Cytogenetic Nomenclature: Guidelines for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature.","author":"Mitelman","year":"1995"},{"key":"2019111801082045200_B23","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3324\/haematol.11296","article-title":"Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients.","volume":"92","author":"Silva","year":"2007","journal-title":"Haematologica"},{"key":"2019111801082045200_B24","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL-transcripts in patients with chronic myeloid leukemia.","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"2019111801082045200_B25","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood-2007-02-072595","article-title":"Trisomy 13 is strongly associated with AML1\/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.","volume":"110","author":"Dicker","year":"2007","journal-title":"Blood"},{"key":"2019111801082045200_B26","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2003-09-3074","article-title":"High incidence of somatic mutations in the AML1\/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.","volume":"103","author":"Harada","year":"2004","journal-title":"Blood"},{"key":"2019111801082045200_B27","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V93.6.1817.406k36_1817_1824","article-title":"Biallelic and heterozygous point mutations in the runt domain of the AML1\/PEBP2alphaB gene associated with myeloblastic leukemias.","volume":"93","author":"Osato","year":"1999","journal-title":"Blood"},{"key":"2019111801082045200_B28","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1158\/0008-5472.CAN-06-1903","article-title":"RUNX1 DNA-binding mutants, associated with minimally differentiated acute myelogenous leukemia, disrupt myeloid differentiation.","volume":"67","author":"Cammenga","year":"2007","journal-title":"Cancer Res"},{"key":"2019111801082045200_B29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/13793","article-title":"Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.","volume":"23","author":"Song","year":"1999","journal-title":"Nat Genet"},{"key":"2019111801082045200_B30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3324\/haematol.10914","article-title":"AML1 mutation and its coexistence with different transcription factor gene families in de novo acute myeloid leukemia (AML): redundancy or synergism.","volume":"92","author":"Auewarakul","year":"2007","journal-title":"Haematologica"},{"key":"2019111801082045200_B31","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1182\/blood-2002-04-1244","article-title":"Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.","volume":"100","author":"Mayotte","year":"2002","journal-title":"Blood"},{"key":"2019111801082045200_B32","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood-2005-03-1113","article-title":"Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells.","volume":"106","author":"Du","year":"2005","journal-title":"Blood"},{"key":"2019111801082045200_B33","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1634\/stemcells.2007-0061","article-title":"Runx1 protects hematopoietic stem\/progenitor cells from oncogenic insult.","volume":"25","author":"Motoda","year":"2007","journal-title":"Stem Cells"},{"key":"2019111801082045200_B34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(02)00081-8","article-title":"Focus on acute leukemias.","volume":"1","author":"Gilliland","year":"2002","journal-title":"Cancer Cell"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/7\/3735\/1483922\/zh800708003735.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/111\/7\/3735\/1483922\/zh800708003735.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T06:08:33Z","timestamp":1574057313000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/111\/7\/3735\/25196\/RUNX1-DNAbinding-mutations-and-RUNX1PRDM16-cryptic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,1]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-07-102533","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,1]]}}}